Full Year 2023 Investor Presentation
8
Investor presentation
Full year 2023
GLP-1 class expansion in the US in 2023
US GLP-1 weekly NBRx prescriptions
Weekly NBRX
scripts ('000s)
00
90
60
60
30
0
Feb
2022
Ozempic Rybelsus®
US GLP-1 TRX market share
TRX share
Class growth: >30%
Novo NordiskⓇ
Total GLP-1 SUS
(millions)
80%
7
6
60%
53.5% 5
43.6% 4
40%
3
24.2%
2
20%
21.6%
6.9% 1
0%
3.0%
0
Jan
2024
Feb
2022
Jan
2024
VictozaⓇ
NN GLP-1
-
dulaglutide tirzepatide
Total monthly GLP-1 scripts
NBRX: New-to-brand prescriptions; TRX: Total prescriptions; NN: Novo Nordisk; Scripts: Prescriptions; US: United States
Note: Class growth calculated based on SU volume for diabetes GLP-1 as Q4 2023 vs Q4 2022
Source: IQVIA Xponent Plantrak, NBRX/TRX data from week ending 12 Jan 2024. Each data point represents a rolling four-week average.View entire presentation